BE2022C501I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2022C501I2 BE2022C501I2 BE2022C501C BE2022C501C BE2022C501I2 BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2 BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020854 | 2003-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2022C501I2 true BE2022C501I2 (en) | 2023-03-07 |
Family
ID=32820637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2022C501C BE2022C501I2 (en) | 2003-01-29 | 2022-01-03 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7300935B2 (en) |
| EP (1) | EP1591446B1 (en) |
| KR (1) | KR101074462B1 (en) |
| CN (2) | CN100360538C (en) |
| AU (1) | AU2004207706B2 (en) |
| BE (1) | BE2022C501I2 (en) |
| BR (1) | BRPI0407082C1 (en) |
| CA (1) | CA2514407C (en) |
| CO (1) | CO5590921A2 (en) |
| CY (2) | CY1114008T1 (en) |
| DK (1) | DK1591446T3 (en) |
| ES (1) | ES2410814T3 (en) |
| FR (1) | FR21C1056I2 (en) |
| HU (1) | HUS2100052I1 (en) |
| IL (1) | IL169869A (en) |
| LT (1) | LTC1591446I2 (en) |
| MX (1) | MXPA05007990A (en) |
| NL (1) | NL301158I2 (en) |
| NO (2) | NO331981B1 (en) |
| NZ (1) | NZ541772A (en) |
| PL (1) | PL214756B1 (en) |
| PT (1) | PT1591446E (en) |
| RU (1) | RU2331648C2 (en) |
| SI (1) | SI1591446T1 (en) |
| WO (1) | WO2004067535A1 (en) |
| ZA (1) | ZA200506611B (en) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| ES2494842T3 (en) * | 2005-07-22 | 2014-09-16 | Takeda Pharmaceutical Company Limited | Agent that prevents early ovulation |
| US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
| WO2010026993A1 (en) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | Method for improving absorbability of preparation, and preparation having improved absorbability |
| KR101430424B1 (en) * | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| EP3111938B1 (en) | 2011-04-01 | 2019-05-08 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| ES2767956T3 (en) * | 2011-11-11 | 2020-06-19 | Gilead Apollo Llc | ACC inhibitors and their uses |
| CN104703992B (en) * | 2012-09-28 | 2019-03-05 | 武田药品工业株式会社 | Preparation method of thienopyrimidine derivatives |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| MY180680A (en) | 2015-02-26 | 2020-12-06 | Takeda Pharmaceuticals Co | Solid preparation |
| CN107922609B (en) | 2015-07-01 | 2020-04-24 | 加州理工学院 | Delivery system based on cationic mucic acid polymers |
| AR106472A1 (en) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | ACC INHIBITORS AND USES OF THE SAME |
| BR112018010453B1 (en) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | ACETYL COA CARBOXYLASE (ACC) INHIBITOR TRIAZOLIC COMPOUNDS |
| CA3004747A1 (en) | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine |
| PT3380480T (en) | 2015-11-25 | 2023-03-14 | Gilead Apollo Llc | Pyrazole acc inhibitors and uses thereof |
| JP2018536660A (en) | 2015-11-25 | 2018-12-13 | ギリアド アポロ， エルエルシー | Ester ACC inhibitors and uses thereof |
| RU2610281C1 (en) * | 2016-02-26 | 2017-02-08 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Method for production of 2-fluorine-3-methylbut-2-enyl amine or its hydrochloride (versions) |
| US10183951B2 (en) | 2016-03-02 | 2019-01-22 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof |
| CN110312512B (en) | 2016-09-30 | 2023-05-09 | 梦欧文科学有限责任公司 | Methods for treating uterine fibroids and endometriosis |
| WO2018060463A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Treatment of prostate cancer |
| PT3600309T (en) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Therapeutic combinations for treating liver diseases |
| JP7348171B2 (en) | 2017-06-05 | 2023-09-20 | キッセイ薬品工業株式会社 | Gonadotropin-releasing hormone antagonist dosing regimen for the treatment of endometriosis |
| WO2019178304A1 (en) * | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| EP3806887A4 (en) | 2018-06-13 | 2022-04-06 | California Institute of Technology | BLOOD-BRAIN BARRIER CROSSING NANOPARTICLES AND METHODS OF TREATMENT THEREOF |
| MX2021002742A (en) | 2018-09-11 | 2021-08-11 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety. |
| EP3873465B1 (en) | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| KR20210100623A (en) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | Compositions and methods for the treatment of estrogen-dependent disorders |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| US20220220123A1 (en) * | 2019-05-15 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline forms of relugolix |
| CN110194776B (en) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | Synthetic method of Ruogeli |
| US20220267347A1 (en) * | 2019-07-29 | 2022-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrimidinedione compounds and uses thereof |
| WO2021026011A1 (en) * | 2019-08-02 | 2021-02-11 | Johnson Matthey Public Limited Company | Solid-state forms of relugolix |
| CN112321602A (en) * | 2019-08-05 | 2021-02-05 | 苏州鹏旭医药科技有限公司 | Preparation method of Ruogeli drug intermediate |
| WO2021023877A2 (en) | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CA3150089A1 (en) | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| CN112390812A (en) * | 2019-08-14 | 2021-02-23 | 苏州鹏旭医药科技有限公司 | Crystalline and amorphous solids of Ruogeli compounds and methods of making the same |
| CN112771052B (en) * | 2019-08-21 | 2023-04-07 | 深圳仁泰医药科技有限公司 | Crystal form of gonadotropin releasing hormone antagonist and preparation method and application thereof |
| EP4041739A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN112745304A (en) * | 2019-10-29 | 2021-05-04 | 上海度德医药科技有限公司 | Preparation method of Relugolix and intermediate compound |
| CN113444105A (en) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | Preparation method of Relugolix |
| CN111333633B (en) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | Intermediate compound of Rayleigh Lu Geli and preparation method and application thereof |
| CN111574534B (en) * | 2020-05-25 | 2021-06-04 | 东莞市东阳光新药研发有限公司 | Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
| IL298587A (en) | 2020-05-29 | 2023-01-01 | Myovant Sciences Gmbh | Combination of solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| CN111793078B (en) * | 2020-07-03 | 2022-02-01 | 东莞市东阳光新药研发有限公司 | Bicyclic nitrogen-containing heteroaryl substituted pyrimidinediones and application thereof |
| CN111875614B (en) * | 2020-07-03 | 2022-04-29 | 东莞市东阳光新药研发有限公司 | Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
| CN111925379B (en) * | 2020-07-31 | 2022-02-15 | 广东东阳光药业有限公司 | Nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof |
| CN111909168B (en) * | 2020-07-31 | 2022-02-01 | 广东东阳光药业有限公司 | Nitrogenous heterocyclic group substituted pyrimidinediones and uses thereof |
| CN112047957B (en) * | 2020-09-09 | 2022-02-01 | 广东东阳光药业有限公司 | Substituted pyrimidinediones and their use |
| CN113754679B (en) * | 2020-09-09 | 2023-04-07 | 广东东阳光药业有限公司 | Substituted pyrimidinediones and their use |
| CN112142757B (en) * | 2020-09-29 | 2022-02-15 | 广东东阳光药业有限公司 | Five-membered nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN112552312B (en) * | 2020-12-07 | 2022-08-05 | 杭州科巢生物科技有限公司 | Synthetic method of Ruogeli or salt thereof |
| CN113620972A (en) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | Rugosril new crystal form and preparation method thereof |
| CN114907370B (en) | 2021-02-10 | 2023-11-03 | 奥锐特药业(天津)有限公司 | High purity thienopyrimidine compounds and process for their preparation |
| CN115073491A (en) * | 2021-03-12 | 2022-09-20 | 上海医药工业研究院 | Rugosril intermediate, preparation method and application thereof |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| CN113135934A (en) * | 2021-04-28 | 2021-07-20 | 北京海美源医药科技有限公司 | Intermediate compound for preparing Ruugeli, preparation method of intermediate compound and preparation method of Ruugeli |
| CN115260211B (en) * | 2021-04-29 | 2024-02-06 | 长春金赛药业有限责任公司 | Thiophene condensed ring derivative, pharmaceutical composition, preparation method and application thereof |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| JP2024540264A (en) * | 2021-11-01 | 2024-10-31 | シャンドン ルイ ファーマシューティカル カンパニー リミテッド | Gonadotropin-releasing hormone antagonists and their preparation and use |
| CN114230576A (en) * | 2021-12-21 | 2022-03-25 | 伊诺药物研究(南京)有限公司 | A kind of preparation method of Relugoli |
| CN114989134B (en) * | 2022-07-14 | 2023-11-14 | 江西同和药业股份有限公司 | Thiophene compound and preparation method and application thereof |
| CN115417883B (en) * | 2022-09-16 | 2024-08-27 | 浙江科聚生物医药有限公司 | Crystal form of rui Lu Geli and preparation method thereof |
| WO2024126674A1 (en) | 2022-12-15 | 2024-06-20 | Medichem, S.A. | Process for the preparation of relugolix |
| WO2024222827A1 (en) * | 2023-04-27 | 2024-10-31 | 山东绿叶制药有限公司 | Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048863A (en) * | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
| UY23948A1 (en) | 1995-02-08 | 2001-10-25 | Takeda Chemical Industries Ltd | DERIVATIVES FROM THYPHENE CONDENSED RINGS, THEIR PRODUCTION AND USE. |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6297379B1 (en) * | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| JP2001316391A (en) * | 2000-02-29 | 2001-11-13 | Takeda Chem Ind Ltd | Method for producing thienopyridine derivative |
| KR20030005205A (en) * | 2000-02-29 | 2003-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | Processes for the production of thienopyrimidine derivatives |
| US20030134863A1 (en) * | 2000-04-13 | 2003-07-17 | Shuichi Furuya | Preventives/remedies for alzheimer's disease |
| JP2001354588A (en) * | 2000-04-13 | 2001-12-25 | Takeda Chem Ind Ltd | Prophylactic and therapeutic agent for alzheimer disease |
| CA2407472A1 (en) * | 2000-06-14 | 2002-10-23 | Takeda Chemical Industries, Ltd. | Sustained release compositions |
| JP2002068982A (en) * | 2000-06-14 | 2002-03-08 | Takeda Chem Ind Ltd | Sustained release composition |
| JP2002080397A (en) * | 2000-07-05 | 2002-03-19 | Takeda Chem Ind Ltd | Therapeutic pharmaceutical formulation for sex hormone-dependent disease |
| US20030176360A1 (en) | 2000-07-05 | 2003-09-18 | Yasutaka Igari | Medicinal preparations for treating sex hormone-dependent diseases |
| WO2002024230A1 (en) * | 2000-09-22 | 2002-03-28 | Takeda Chemical Industries, Ltd. | Solid preparations |
| JP2002167327A (en) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | Solid formulation |
| WO2002043766A1 (en) * | 2000-11-29 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Medicinal compositions and process for producing the same |
| AU2002221139A1 (en) * | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| EP1370562A1 (en) * | 2001-02-14 | 2003-12-17 | Warner-Lambert Company LLC | Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| JP5072166B2 (en) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | Thienopyrimidine compound, production method and use thereof |
| EP1479684A4 (en) | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
| AU2003211877A1 (en) | 2002-03-11 | 2003-09-22 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
| JP2004002321A (en) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | Therapeutic agent for sex hormone dependent disease |
| JP2004002377A (en) * | 2002-04-12 | 2004-01-08 | Takeda Chem Ind Ltd | Hot flash preventing and treating agent |
| AU2003236039A1 (en) | 2002-04-12 | 2003-10-27 | Takeda Pharmaceutical Company Limited | Preventives/remedies for hotflash |
-
2004
- 2004-01-28 CA CA2514407A patent/CA2514407C/en not_active Expired - Fee Related
- 2004-01-28 PL PL378002A patent/PL214756B1/en unknown
- 2004-01-28 US US10/544,069 patent/US7300935B2/en not_active Expired - Lifetime
- 2004-01-28 ES ES04705950T patent/ES2410814T3/en not_active Expired - Lifetime
- 2004-01-28 ZA ZA200506611A patent/ZA200506611B/en unknown
- 2004-01-28 WO PCT/JP2004/000741 patent/WO2004067535A1/en not_active Application Discontinuation
- 2004-01-28 SI SI200432035T patent/SI1591446T1/en unknown
- 2004-01-28 EP EP04705950A patent/EP1591446B1/en not_active Expired - Lifetime
- 2004-01-28 BR BRPI0407082A patent/BRPI0407082C1/en not_active IP Right Cessation
- 2004-01-28 RU RU2005127052/04A patent/RU2331648C2/en active
- 2004-01-28 KR KR1020057014100A patent/KR101074462B1/en not_active Expired - Lifetime
- 2004-01-28 AU AU2004207706A patent/AU2004207706B2/en active Active
- 2004-01-28 NZ NZ541772A patent/NZ541772A/en not_active IP Right Cessation
- 2004-01-28 CN CNB2004800087989A patent/CN100360538C/en not_active Expired - Lifetime
- 2004-01-28 DK DK04705950.6T patent/DK1591446T3/en active
- 2004-01-28 CN CNA2007101869688A patent/CN101153042A/en active Pending
- 2004-01-28 MX MXPA05007990A patent/MXPA05007990A/en active IP Right Grant
- 2004-01-28 PT PT47059506T patent/PT1591446E/en unknown
-
2005
- 2005-07-25 IL IL169869A patent/IL169869A/en active IP Right Grant
- 2005-08-25 NO NO20053974A patent/NO331981B1/en not_active IP Right Cessation
- 2005-08-25 CO CO05084855A patent/CO5590921A2/en unknown
-
2007
- 2007-08-31 US US11/848,939 patent/US8058280B2/en active Active
-
2011
- 2011-09-23 US US13/242,541 patent/US8735401B2/en not_active Expired - Lifetime
-
2013
- 2013-05-29 CY CY20131100419T patent/CY1114008T1/en unknown
-
2014
- 2014-04-11 US US14/251,119 patent/US9346822B2/en not_active Expired - Lifetime
-
2021
- 2021-11-19 HU HUS2100052C patent/HUS2100052I1/en unknown
- 2021-11-19 FR FR21C1056C patent/FR21C1056I2/en active Active
- 2021-11-24 LT LTPA2021529C patent/LTC1591446I2/lt unknown
- 2021-12-16 NO NO2021052C patent/NO2021052I1/en unknown
- 2021-12-22 CY CY2021039C patent/CY2021039I1/en unknown
- 2021-12-31 NL NL301158C patent/NL301158I2/en unknown
-
2022
- 2022-01-03 BE BE2022C501C patent/BE2022C501I2/fr unknown